STUDY OF RADIUM-223 DICHLORIDE VERSUS PLACEBO AND TREATMENT WITH EXEMESTANE / EVEROLIMUS IN SUBJECTS WITH BONE PREDOMINANT HER2 (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) NEGATIVE HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER: